Hantz Financial Services Inc. Sells 7,003 Shares of Bruker Co. (NASDAQ:BRKR)

Hantz Financial Services Inc. reduced its stake in Bruker Co. (NASDAQ:BRKR) by 64.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,876 shares of the medical research company’s stock after selling 7,003 shares during the period. Hantz Financial Services Inc.’s holdings in Bruker were worth $268,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. FMR LLC raised its stake in Bruker by 21.4% during the 3rd quarter. FMR LLC now owns 14,306,122 shares of the medical research company’s stock worth $987,981,000 after buying an additional 2,521,904 shares during the period. Marshall Wace LLP raised its position in shares of Bruker by 127.8% during the second quarter. Marshall Wace LLP now owns 1,389,537 shares of the medical research company’s stock worth $88,666,000 after purchasing an additional 779,549 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Bruker by 8.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,277,273 shares of the medical research company’s stock worth $81,508,000 after purchasing an additional 101,539 shares in the last quarter. Bank of New York Mellon Corp grew its position in Bruker by 3.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 966,069 shares of the medical research company’s stock valued at $61,645,000 after purchasing an additional 27,870 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in Bruker by 11.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 899,638 shares of the medical research company’s stock worth $62,129,000 after buying an additional 94,612 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on BRKR. Wells Fargo & Company reduced their price objective on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th. Citigroup cut their price target on Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Barclays lowered their price objective on Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a research note on Wednesday, November 6th. TD Cowen cut their target price on Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research report on Wednesday, November 6th. Finally, Wolfe Research lowered Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Bruker currently has an average rating of “Moderate Buy” and an average price target of $79.36.

Bruker Trading Up 0.8 %

NASDAQ BRKR opened at $58.37 on Tuesday. The business’s fifty day moving average is $60.63 and its 200-day moving average is $63.91. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73. The stock has a market capitalization of $8.85 billion, a price-to-earnings ratio of 28.06, a PEG ratio of 3.89 and a beta of 1.20. Bruker Co. has a one year low of $48.07 and a one year high of $94.86.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing the consensus estimate of $0.61 by ($0.01). Bruker had a return on equity of 21.52% and a net margin of 9.41%. The company had revenue of $864.40 million during the quarter, compared to the consensus estimate of $866.46 million. During the same period in the prior year, the firm posted $0.74 EPS. The business’s revenue was up 16.4% on a year-over-year basis. Equities research analysts predict that Bruker Co. will post 2.4 EPS for the current year.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 16th. Shareholders of record on Monday, December 2nd will be paid a $0.05 dividend. The ex-dividend date is Monday, December 2nd. This represents a $0.20 annualized dividend and a dividend yield of 0.34%. Bruker’s payout ratio is presently 9.62%.

Insider Activity

In other news, CEO Frank H. Laukien acquired 100,000 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were acquired at an average cost of $50.14 per share, for a total transaction of $5,014,000.00. Following the purchase, the chief executive officer now owns 38,439,563 shares of the company’s stock, valued at approximately $1,927,359,688.82. The trade was a 0.26 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 28.30% of the company’s stock.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.